| References: |
CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013. For the detailed information of GSK1014802（CNV1014802，GSK-2）, the solubility of GSK1014802（CNV1014802，GSK-2） in water, the solubility of GSK1014802（CNV1014802，GSK-2） in DMSO, the solubility of GSK1014802（CNV1014802，GSK-2） in PBS buffer, the animal experiment (test) of GSK1014802（CNV1014802，GSK-2）, the cell expriment (test) of GSK1014802（CNV1014802，GSK-2）, the in vivo, in vitro and clinical trial test of GSK1014802（CNV1014802，GSK-2）, the EC50, IC50,and affinity,of GSK1014802（CNV1014802，GSK-2）, For the detailed information of GSK1014802（CNV1014802，GSK-2）, the solubility of GSK1014802（CNV1014802，GSK-2） in water, the solubility of GSK1014802（CNV1014802，GSK-2） in DMSO, the solubility of GSK1014802（CNV1014802，GSK-2） in PBS buffer, the animal experiment (test) of GSK1014802（CNV1014802，GSK-2）, the cell expriment (test) of GSK1014802（CNV1014802，GSK-2）, the in vivo, in vitro and clinical trial test of GSK1014802（CNV1014802，GSK-2）, the EC50, IC50,and affinity,of GSK1014802（CNV1014802，GSK-2）, Please contact DC Chemicals. |
